|
English
|
正體中文
|
简体中文
|
2822924
|
|
???header.visitor??? :
30019764
???header.onlineuser??? :
1053
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"cameron s"???jsp.browse.items-by-author.description???
Showing items 1-6 of 6 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-15T01:08:59Z |
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
|
Naing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; Chia-Chi Lin; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M. |
| 臺大學術典藏 |
2022-09-15T01:08:53Z |
PD-1 blockade in anaplastic thyroid carcinoma
|
Capdevila J.; Wirth L.J.; Ernst T.; Aix S.P.; Chia-Chi Lin; Ramlau R.; Butler M.O.; Delord J.-P.; Gelderblom H.; Ascierto P.A.; Fasolo A.; F?hrer D.; H?tter-Kr?nke M.L.; Forde P.M.; Wrona A.; Santoro A.; Sadow P.M.; Szpakowski S.; Wu H.; Bostel G.; Faris J.; Cameron S.; Varga A.; Taylor M. |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer
|
Chia-Chi Lin; Taylor M; Boni V; Brunsvig P.F; Geater S.L; Salvagni S; Garrido Lopez P; ?zg?ro?lu M; Sriuranpong V; Ponce Aix S; Ascierto P.A; Fasolo A; Sezer A; Kowalski D.M; Faris J.E; Cameron S; Mataraza J; Wu H; Antona V; Ochoa de Olza M. |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
|
Naing A; Gainor J.F; Gelderblom H; Forde P.M; Butler M.O; Chia-Chi Lin; Sharma S; Ochoa De Olza M; Varga A; Taylor M; Schellens J.H.M; Wu H; Sun H; Silva A.P; Faris J; Mataraza J; Cameron S; Bauer T.M. |
| 臺大學術典藏 |
2020-03-23T07:18:53Z |
Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial
|
Bardia A.; Bardia A.;Parton M.;Kummel S.;Estevez L.G.;Chiun-Sheng Huang;Cortes J.;Ruiz-Borrego M.;Telli M.L.;Martin-Martorell P.;Lopez R.;Beck J.T.;Ismail-Khan R.;Chen S.-C.;Hurvitz S.A.;Mayer I.A.;Carreon D.;Cameron S.;Liao S.;Baselga J.;Kim S.-B.; Parton M.; Kummel S.; Estevez L.G.; CHIUN-SHENG HUANG; Cortes J.; Ruiz-Borrego M.; Telli M.L.; Martin-Martorell P.; Lopez R.; Beck J.T.; Ismail-Khan R.; Chen S.-C.; Hurvitz S.A.; Mayer I.A.; Carreon D.; Cameron S.; Liao S.; Baselga J.; Kim S.-B. |
| 國立臺灣大學 |
1994-07 |
EFFICIENT SYNTHESIS OF POLYHYDROXYLATED FULLERENE DERIVATIVES VIA HYDROLYSIS OF POLYCYCLOSULFATED PRECURSORS
|
CHIANG, LY; WANG, LY; SWIRCZEWSKI, JW; SOLED, S; CAMERON, S |
Showing items 1-6 of 6 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
